- Home
- NGNE vs LPAA Comparison
NGNE vs LPAA Comparison
Compare NGNE & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LPAA
- Stock Information
- Founded
- NGNE 2003
- LPAA 2024
- Country
- NGNE United States
- LPAA United States
- Employees
- NGNE N/A
- LPAA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LPAA
- Sector
- NGNE Health Care
- LPAA
- Exchange
- NGNE Nasdaq
- LPAA Nasdaq
- Market Cap
- NGNE 325.3M
- LPAA 299.3M
- IPO Year
- NGNE N/A
- LPAA 2024
- Fundamental
- Price
- NGNE $18.48
- LPAA $10.48
- Analyst Decision
- NGNE Strong Buy
- LPAA
- Analyst Count
- NGNE 7
- LPAA 0
- Target Price
- NGNE $41.86
- LPAA N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- LPAA 12.8K
- Earning Date
- NGNE 08-11-2025
- LPAA 01-01-0001
- Dividend Yield
- NGNE N/A
- LPAA N/A
- EPS Growth
- NGNE N/A
- LPAA N/A
- EPS
- NGNE N/A
- LPAA 0.35
- Revenue
- NGNE N/A
- LPAA N/A
- Revenue This Year
- NGNE N/A
- LPAA N/A
- Revenue Next Year
- NGNE N/A
- LPAA N/A
- P/E Ratio
- NGNE N/A
- LPAA $29.76
- Revenue Growth
- NGNE N/A
- LPAA N/A
- 52 Week Low
- NGNE $6.88
- LPAA $9.66
- 52 Week High
- NGNE $74.49
- LPAA $10.70
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- LPAA 70.12
- Support Level
- NGNE $19.59
- LPAA $10.43
- Resistance Level
- NGNE $20.46
- LPAA $10.45
- Average True Range (ATR)
- NGNE 1.23
- LPAA 0.01
- MACD
- NGNE -0.20
- LPAA 0.00
- Stochastic Oscillator
- NGNE 13.37
- LPAA 100.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.